Sequential Launches Multi-Omic Studies to Advance Human Health Characterization

LONDON, April 2, 2025 /PRNewswire/ -- Sequential, a leader in microbiome research, is proud to announce the launch of its Multi-Omic Studies, a groundbreaking initiative that integrates human and microbial analysis to redefine skin health research. By combining advanced genetic, metabolic, and microbiome profiling, Sequential is setting a new standard in clinical testing for personal care and pharmaceutical industries.

"Our Multi-Omic approach bridges the gap between host biology and microbial interactions, offering unparalleled insights into skin health," said Dr. Albert Dashi, Chief Science Officer at Sequential. "By leveraging cutting-edge technologies, we empower brands to develop more precise, effective, and scientifically validated formulations."

Sequential's Multi-Omic Studies provide a comprehensive view of skin health through:

• Human-Centered Analysis: Includes SNP detection, metabolomics, gene expression, protein profiling, and lipid profiling to assess how the human body responds to formulations at a molecular level.
• Microbiome-Centered Analysis: Utilizes Sequential's proprietary Smart Probes™ (qPCR), 16S sequencing, ITS sequencing, shotgun metagenomics, and metatranscriptomics to evaluate microbial shifts in response to treatments.

With over 25,000 clinical skin microbiome samples in its database, Sequential continues to drive precision innovation in microbiome research. This new initiative not only enhances product efficacy testing but also advances scientific understanding of skin health.

Sequential invites brands and researchers to collaborate in shaping the future of personalized skin care and microbiome science.

Sequential is a global leader in the skin microbiome field, a team of PhD experts in testing products and their effect on the human microbiome (skin, scalp, oral, vulva). An Innovate UK- and Enterprise Singapore-backed company, with labs in London, New York City and Singapore. Awarded the title "Most Significant" Testing Solution in the Industry - (C&T, 2022). To date, Sequential has amassed over 25,000 human skin microbiome samples and corresponding formulations tested in vivo on the skin. With this vast genomic dataset, Sequential are figuring out optimal formulations that could potentially alleviate skin conditions, for example – acne, atopic dermatitis and rosacea. They have been supported by. They have raised $5,000,000 USD to date from Innovate UK, Enterprise SG, A*STAR (Genome Institute of Singapore), SOSV, Corundum Systems Biology and other leading organisations.

Logo: https://mma.prnewswire.com/media/2619118/5165458/Sequential_Skin_Logo.jpg

SOURCE Sequential